Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the ...

The new program is validated in a set of clinical pedigrees demonstrating its practical accuracy and relevance to the field. Collectively, the data are compelling and support the major conclusions of ...

In a bold step forward for AI-generated filmmaking, Google has unveiled Veo 3.1, the latest version of its generative video ...

(NYSE: CALX) today announced the next generation of the Calix Broadband Platform, fully evolved for agentic AI and purpose-built to address the workflow, data, security, and insight requirements of ...

Pennsylvania-based Conestoga Capital Advisors sold 855,435 Vertex shares for an estimated $24.8 million based on average ...

Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...

A real braindump is when someone takes the official exam, memorizes as many questions as possible, and publishes them online.

Although teplizumab doesn’t work for everyone and how much it delays progression varies, it has inspired new directions in ...

BioMarin will host a conference call and webcast to discuss third quarter 2025 financial results today, Monday, October 27, 2025, at 4:30 p.m. ET. This event can be accessed through this link or on ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

On one wall of endocrinologist Kevan Herold’s office hangs artwork by a girl who joined one of his type 1 diabetes trials when she was 11 years old. The girl was diagnosed with stage 2 of the disease, ...